NanoViricides Restructures Agreements to Alleviate Financial Stress
TipRanksFeb 16 17:03 ET
Express News | EF Hutton Reiterates Buy on Nanoviricides, Maintains $6.5 Price Target
Moomoo 24/7Feb 16 07:14 ET
Nanoviricides Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/16/2024 470.18% EF Hutton → $6.5 Reiterates Buy → Buy 06/01/2023 360.53% EF Hutton → $5.25 Assumes → Bu
BenzingaFeb 16 07:13 ET
Nanoviricides Q2 EPS $(0.18) Down From $(0.15) YoY; As Of December 31, 2023, We Had Cash And Cash Equivalent Current Assets Balance Of Approximately $5.31M. Additional Agreements Have Resulted In A Further Approximately $2.5M Available Cash
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) per share from the same period last year.
BenzingaFeb 15 06:44 ET
NanoViricides GAAP EPS of -$0.18
Seeking AlphaFeb 15 06:38 ET
NanoViricides Has Filed Its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarte
AccesswireFeb 15 06:30 ET
NanoViricides Highlights Lead Asset NV-387's Potential to Revolutionize the Treatment of Antiviral Infections
InvestingFeb 1 08:58 ET
Express News | NanoViricides Explains That The Demonstration Of Strong Safety And Tolerability Of NV-COV-2 Oral Drug Products Has Implications Beyond COVID
Moomoo 24/7Feb 1 06:26 ET
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could Be As Revolutionary as Antibiotics
SHELTON, CT / ACCESSWIRE / February 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicin
AccesswireFeb 1 06:20 ET
NanoViricides Reports Positive Safety Results for COVID Drug Candidate
Seeking AlphaJan 29 12:52 ET
Express News | NanoViricides Says The Healthy Subjects Part Of The Phase 1a/1b Clinical Trial Of NV-CoV-2 Was Completed Successfully And No Adverse Events Were Reported In Any Of The Ascending Dose Cohorts
Moomoo 24/7Jan 29 06:33 ET
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 With No Adverse Events Found
SHELTON, CT / ACCESSWIRE / January 29, 2024 / NanoViricides, Inc. , a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology,
AccesswireJan 29 06:30 ET
NanoViricides Updates Progress on Phase 1a/1b Clinical Trial of Antiviral Drug Candidate NV-387
Yahoo FinanceNov 29, 2023 13:32 ET
Express News | NanoViricides Has Completed The Single-ascending Dose Part Of The Phase 1A/1B Human Trial Of NV-COV-2, A Broad-spectrum Antiviral Drug, Recruitment For The Multiple-ascending Dose Part Was Also Completed
Moomoo 24/7Nov 28, 2023 06:47 ET
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedici
AccesswireNov 28, 2023 06:40 ET
NanoViricides Has Filed Its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications
SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal first quarter ending
AccesswireNov 15, 2023 06:45 ET
Broad-Spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial Is Highly Effective in an Animal Model for MPox and Smallpox Drug Development
SHELTON, CT / ACCESSWIRE / November 14, 2023 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines techn
AccesswireNov 14, 2023 06:45 ET
NanoViricides, Inc. Has Filed Its Annual Report: Broad-spectrum Antiviral NV-387 (NV-CoV-2) in Phase 1a/1b Clinical Trial Is Highly Active Against Coronaviruses as Well as RSV
SHELTON, CT / ACCESSWIRE / October 16, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 202
AccesswireOct 16, 2023 06:45 ET
NanoViricides, Inc. to Present at the Partnership Opportunities in Drug Delivery Conference in Boston on October 16, 2023 at 6:07pm ET
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be presenting a talk in person at t
AccesswireOct 12, 2023 06:45 ET
NanoViricides Shares Rise On Successful Results Of Phase 1a/1b Human Clinical Trial Of NV-CoV-2
RTTNewsAug 21, 2023 13:12 ET
No Data
No Data